Platelet-rich fibrin treatment of medication-related osteonecrosis of the jaw followed up for two years

Meri Hristamyan; Veselka Hristamyan

doi:10.14748/bmr.v31.7715

Platelet-rich fibrin treatment of medication-related osteonecrosis of the jaw followed up for two years

Meri Hristamyan, Veselka Hristamyan

Abstract

The use of platelet-rich fibrin (PRF) in surgery represents a new alternative method of treatment of Medication-related osteonecrosis of the jaws. This report presents a case of a patient undergoing PRF treatment. The patient is a 76-year-old male who was admitted for treatment in 2018 at the Clinic for Maxillofacial Surgery with osteonecrosis of the lower jaw on the right side. In 2012, he was diagnosed with prostate cancer and underwent bilateral orchiectomy followed by a therapy with Denosumab (trade names Prolia and Xgeva), a monoclonal antibody that works as receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor. The patient was diagnosed with medication-related osteonecrosis of the mandible jaw in 2017 after tooth extraction. The treatment was performed at the Clinic of Maxillofacial Surgery of St. George University Hospital, Plovdiv, Bulgaria. When initial antibiotic therapy failed, surgical therapy was undertaken using PRF. The patient was followed-up for two years and no osteonecrotic lesion was detected recurring in the intervention area.

Keywords

platelet-rich fibrin, jaw osteonecrosis, maxillofacial surgery

Full Text

References

American Association of Oral and Maxillofacial Surgeons. https://www.aaoms.org/

Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(3):e45-50. doi: 10.1016/j. tripleo.2005.07.009.

Tsolov R. Treatment of bisphosphonate necrosis of the jaws with the help of platelet-rich fibrin. Med Magazine 2019; 61: 120-123.

Tsolov R, Firkova E, Yordanov G. Comparative analysis of the healing process after conservative and surgical treatment of Medicamentally Induced Osteonecrosis of the Jaws. Bul Med J 2019; 2: 21-26.

Bartl R, Frisch B, von Tresckow E, Bartl C. Bisphosphonates in Medical Practice Actions, Side Effects, Indications, Strategies. Berlin/New York: Springer. 2007.

Chandran P, Sivadas A. Platelet-rich fibrin: Its role in periodontal regeneration. Saudi J Dent Res 2014;5:117-122. doi: 10.1016/j.ksujds.2013.09.001.

Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999;14(4):529-35.

Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: a trial study. Clin Oral Invest 2017;21(7):2165-2172. doi: 10.1007/s00784-016-2004-z.

Tsolov R, Firkova E, Yordanov G. Bisphosphonate induced osteonecrosis of the jaws - X-ray results 6 months after ureatment. Contemp Med 2019; 1:13-30.

DOI: http://dx.doi.org/10.14748/bmr.v31.7715